Basic Information
| Drug ID | DDPD00515 |
|
| Drug Name | Cisplatin | |
| Molecular Weight | 300.05 | |
| Molecular Formula | Cl2H6N2Pt | |
| CAS Number | 15663-27-1 | |
| SMILES | [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] | |
| External Links | ||
| DRUGBANK | DB00515 | |
| T3DB | T3D4686 | |
| PubChem Compound | 2767 | |
| PDR | 1472 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | -2.19 | - | -2.19 | - | HANSCH,C ET AL. (1995) |
| Melting Point | 270.0 | ℃ | 270 | ℃ | PhysProp |
| Water Solubility | 2530.0 | mg/L | 2530 | mg/L | AMUNDSEN,AR & STERN,EW 1982) |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| C Max | 3400.0 | ng/ml | 3.4±1.1 | mcg/ml | ovarian cancer; | The Pharmacological Basis of Therapeutics | C Max | 1000.0 | ng/ml | 1.0±0.4 | mcg/ml | ovarian cancer; | The Pharmacological Basis of Therapeutics |
| Clearance | 15.5 | L/h/m2 | 15-16 | L/h/m2 | Total clearance; intravenous infusion, IV in drop; | DRUGBANK | Clearance | 3.7 | L/h/m2 | 62.0 | ml/min/m2 | Renal clearance; intravenous infusion, IV in drop; | DRUGBANK | Clearance | 3.0 | L/h/m2 | 50.0 | ml/min/m2 | Renal clearance; intravenous infusion, IV in drop; | DRUGBANK | Clearance | 0.38 | L/h/kg | 6.3±1.2 | ml/min/kg | ovarian cancer; patients; | The Pharmacological Basis of Therapeutics |
| Volume of Distribution | 11.5 | L/m2 | 11-12.0 | L/m2 | at steady state; | DRUGBANK | Volume of Distribution | 0.28 | L/kg | 0.28±0.07 | L/kg | ovarian cancer; patients; | The Pharmacological Basis of Therapeutics |
| Half-life | 0.42 | h | 20-30 | min | DRUGBANK | Half-life | 0.50 | h | 30 | min | elimination half-life; | DRUGBANK | Half-life | 120.0 | h | >=5 | day | plasma proteins; | DRUGBANK | Half-life | 0.53 | h | 0.53±0.10 | h | The Pharmacological Basis of Therapeutics |
| Eliminate Route | 2.3 | % | 2.3±9 | % | Urinary excretion; ovarian cancer; Unchanged drug; | The Pharmacological Basis of Therapeutics |
| Protein Binding | 90.0 | % | 90 | % | plasma proteins; intravenous infusion, IV in drop; | DRUGBANK |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 40.0 | mg/m^2 | 40 | mg/m^2 | intravenous injection, IV | Cisplatin | cisplatin | PDR |
| Max dose for adolescents | 40.0 | mg/m2 | 40 | mg/m^2 | intravenous injection, IV | Cisplatin | cisplatin | PDR |
| Max dose for adults | 100.0 | mg/m2 | 100 | mg/m2 | intravenous injection, IV | Cisplatin | cisplatin | PDR |
| Max dose for geriatric | 100.0 | mg/m2 | 100 | mg/m2 | intravenous injection, IV | Cisplatin | cisplatin | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1